Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on April 6, 2017. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On April 6, 2017, the Board of Directors appointed Deborah Dunsire, M.D., as a Class II director, effective immediately. Her term will expire at the 2018 annual meeting of stockholders. Concurrent with this appointment, the Board size was fixed at eight directors. Dr. Dunsire was also appointed to the Research and Development Committee.
Compensation and Arrangements
- Stock Option Grant: Dr. Dunsire was granted an option to purchase up to 15,000 shares of common stock with an exercise price of $58.59, based on the closing price on April 6, 2017.
- Compensation Policy: She will receive compensation consistent with the Company's Non-Employee Director Compensation Policy.
- Indemnification: An indemnification agreement was entered into on April 6, 2017, requiring the Company to indemnify Dr. Dunsire to the fullest extent permitted under Delaware law.
Management Commentary and Background
Dr. Dunsire brings over 25 years of pharmaceutical industry experience. Her background includes serving as President and CEO of Xtuit Pharmaceuticals, FORUM Pharmaceuticals, and Millennium Pharmaceuticals (later Millennium: The Takeda Oncology Company). She also held executive roles at Takeda Pharmaceutical Company Limited and Novartis.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 15,000 share option grant on potential dilution.
- Review the Company's Non-Employee Director Compensation Policy to understand the full scope of cash and equity compensation for Dr. Dunsire.
- Confirm the composition of the Board's Research and Development Committee following this appointment.
- Check for any subsequent filings regarding the exercise or vesting of the granted stock options.